Although CD8+ CTL could induce more than 90% antigen-specific lysis of their target cells in an in vivo cytotoxicity assay (data not shown), they induced less than 30% tumor-free survival as a single-cell therapy (Figure 5c). The gene discussed is CD8A; the disease is neoplasm.